PMID- 38307571
OWN - NLM
STAT- MEDLINE
DCOM- 20240205
LR  - 20240206
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 44
IP  - 2
DP  - 2024 Feb
TI  - Relationship Between Adverse Events and Progression-free Survival in Patients 
      Receiving Cabozantinib for Previously Treated Metastatic Renal Cell Carcinoma.
PG  - 781-786
LID - 10.21873/anticanres.16869 [doi]
AB  - BACKGROUND/AIM: Although the adverse events (AEs) of drugs, such as sunitinib and 
      axitinib, have been shown to predict treatment responses, evidence to support 
      cabozantinib-induced AEs as predictors of responses to treatment for metastatic 
      renal cell carcinoma (mRCC) is limited. Therefore, we herein investigated the 
      relationship between AE profiles and progression-free survival (PFS) in patients 
      receiving cabozantinib for previously treated mRCC. PATIENTS AND METHODS: The 
      present study retrospectively analyzed 40 patients receiving cabozantinib for 
      previously treated mRCC between July 2020 and August 2022. PFS was estimated 
      using the Kaplan-Meier method and the impact of several parameters, including 
      cabozantinib-induced AEs, on PFS was investigated by a Cox proportional 
      regression analysis. RESULTS: The median observation period was 15 (2-29) months, 
      during which time 31 patients (77.5%) progressed, with median PFS of 11 months. 
      Thirty-nine patients (97.5%) developed at least one AE. Liver toxicity occurred 
      in 16 patients (40.0%) and hand-foot syndrome, hypertension, and diarrhea in 14 
      each (17.5%). Only hypertension correlated with longer PFS. A multivariate 
      analysis identified hypertension as an independent prognostic factor for PFS 
      (p=0.049). CONCLUSION: These results suggest the potential of treatment-induced 
      hypertension as a significant predictor of prolonged PFS in patients receiving 
      cabozantinib for mRCC.
CI  - Copyright (c) 2024 International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Sato, Ryo
AU  - Sato R
AD  - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan; 
      rsato02@hama-med.ac.jp.
FAU - Matsushita, Yuto
AU  - Matsushita Y
AD  - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
FAU - Takemura, Ayana
AU  - Takemura A
AD  - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
FAU - Sugiyama, Momoko
AU  - Sugiyama M
AD  - Department of Urology, Seirei Mikatahara General Hospital, Hamamatsu, Japan.
FAU - Watanabe, Kyohei
AU  - Watanabe K
AD  - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
FAU - Watanabe, Hiromitsu
AU  - Watanabe H
AD  - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
FAU - Tamura, Keita
AU  - Tamura K
AD  - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
FAU - Motoyama, Daisuke
AU  - Motoyama D
AD  - Department of Developed Studies for Advanced Robotic Surgery, Hamamatsu 
      University School of Medicine, Hamamatsu, Japan.
FAU - Nagata, Masao
AU  - Nagata M
AD  - Department of Urology, Hamamatsu Medical Center, Hamamatsu, Japan.
FAU - Otsuka, Atsushi
AU  - Otsuka A
AD  - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
FAU - Furuse, Hiroshi
AU  - Furuse H
AD  - Department of Urology, Seirei Mikatahara General Hospital, Hamamatsu, Japan.
FAU - Miyake, Hideaki
AU  - Miyake H
AD  - Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antineoplastic Agents)
RN  - 1C39JW444G (cabozantinib)
RN  - 0 (Anilides)
RN  - 0 (Pyridines)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Renal Cell/pathology
MH  - Progression-Free Survival
MH  - *Antineoplastic Agents/adverse effects
MH  - *Kidney Neoplasms/pathology
MH  - Retrospective Studies
MH  - Anilides/adverse effects
MH  - *Hypertension/drug therapy
MH  - *Pyridines
OTO - NOTNLM
OT  - Renal cell carcinoma
OT  - adverse event
OT  - cabozantinib
OT  - progression-free survival
EDAT- 2024/02/03 00:41
MHDA- 2024/02/05 06:42
CRDT- 2024/02/02 20:34
PHST- 2023/12/21 00:00 [received]
PHST- 2024/01/09 00:00 [revised]
PHST- 2024/01/10 00:00 [accepted]
PHST- 2024/02/05 06:42 [medline]
PHST- 2024/02/03 00:41 [pubmed]
PHST- 2024/02/02 20:34 [entrez]
AID - 44/2/781 [pii]
AID - 10.21873/anticanres.16869 [doi]
PST - ppublish
SO  - Anticancer Res. 2024 Feb;44(2):781-786. doi: 10.21873/anticanres.16869.